Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-01-27 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
Preliminary short form prospectus – English.pdf
Regulatory Filings
2020-01-27 English
Qualification certificate.pdf
Regulatory Filings Classification · 100% confidence The document is a Qualification Certificate addressed to multiple Canadian securities commissions regarding a preliminary short form prospectus filed under National Instrument 44-101. It is signed by the CFO certifying compliance with regulatory requirements for filing a prospectus. The document is short (2817 characters) and primarily serves as a certification related to a prospectus filing, not the prospectus or financial report itself. It does not contain financial statements or substantive financial data but is an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2020-01-27 English
Material change report - French.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'Déclaration de changement important' (Declaration of Material Change) and details a private placement financing transaction by Tetra Bio-Pharma Inc. It describes the issuance of units, subscription by insiders, regulatory approvals, and related financial terms. The document is a formal announcement of a financing event, specifically a private placement, including insider participation and regulatory compliance. It does not contain financial statements or detailed financial performance data, nor is it a full report or earnings release. It is not a proxy, AGM material, or a legal proceeding update. The content fits the category of Capital/Financing Update (CAP), as it provides an update on the company's fundraising activity and capital structure changes through a private placement.
2020-01-27 English
Material change report - French.pdf
Capital/Financing Update Classification · 100% confidence The document is titled 'ANNEXE 51-102A3 DÉCLARATION DE CHANGEMENT IMPORTANT' which translates to 'Declaration of Material Change'. It details a private placement financing transaction by Tetra Bio-Pharma Inc., including the issuance of units, subscription by insiders, regulatory exemptions, and related approvals. The document is a formal disclosure of a significant corporate event related to capital raising. It is not a full financial report, audit, or earnings release, nor is it a meeting presentation or voting result. The content fits the category of a Capital/Financing Update as it announces the closing of a private placement and details about the issuance of securities and related insider participation. The document length is over 10,000 characters, indicating it is a substantive disclosure rather than a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-01-27 English
Material change report - French.pdf
Capital/Financing Update Classification · 95% confidence The document is a formal declaration of a significant change related to the closing of a unit offering by Tetra Bio-Pharma Inc. It details the terms of the financing, including the number of units sold, pricing, use of proceeds, and insider participation. The document references regulatory compliance under Canadian securities regulations and TSX Venture Exchange rules. It is not a full financial report, earnings release, or management discussion, but rather an announcement of a capital raising event and related insider transaction disclosures. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (7467 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2020-01-27 English
Material change report - French.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'ANNEXE 51-102A3 DÉCLARATION DE CHANGEMENT IMPORTANT' and details a significant change involving Tetra Bio-Pharma Inc. acquiring Panag Pharma Inc. It includes detailed descriptions of the transaction terms, business rationale, impact on the company, related party interests, approval procedures, and regulatory references such as Règlement 61-101 and Règlement 51-102. The content is a formal declaration of a material change, typical of regulatory filings required by securities commissions to disclose significant corporate events. It is not a financial report, earnings release, or management discussion, but a regulatory announcement of a material corporate transaction. Therefore, it fits best under Regulatory Filings (RNS). The document length (10,691 characters) and detailed content confirm it is not a brief announcement or a report publication notice but a substantive regulatory filing.
2020-01-27 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.